NCT05926713 Evaluate the Effect of Dietary Supplement Combined Exercise Among Patients With Sarcopenia Comorbid With Lung Disease
| NCT ID | NCT05926713 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Orient Europharma Co., Ltd. |
| Condition | Sarcopenia |
| Study Type | INTERVENTIONAL |
| Enrollment | 100 participants |
| Start Date | 2023-03-01 |
| Primary Completion | 2032-10-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 100 participants in total. It began in 2023-03-01 with a primary completion date of 2032-10-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This trial is a prospective multi-center study. The purpose of this study is to evaluate the effect of dietary supplement combined with supervised exercised on the physical performance, body composition and lung function among patients with Sarcopenia and severe Sarcopenia in chronic lung disease. After participants enroll in this study, 12-week clinical trial will be conducted to analyze the improvement regarding Sarcopenia and different severity of Sarcopenia before and after the intervention of exercise and nutritional products, which can further provide reference for clinical intervention and rehabilitation.
Eligibility Criteria
Inclusion Criteria: * Outpatients with COPD (chronic obstructive pulmonary disease) or ILD (interstitial lung disease) from Department of Chest medicine in Taichung Veterans General Hospital, judged by the doctor that they do not need hospitalization or emergent treatment. * Outpatients who meet the diagnostic criteria for Sarcopenia after evaluation by a physician. Exclusion Criteria: * Patients who refuse to sign the consent form * Patients who are under 20 years old * Patients who are bedridden or unable to walk due to physical disabilities * Patients with terminal cancer or human-acquired immunodeficiency syndrome * Patients with edema (grading pitting edema +2)
Contact & Investigator
Pin-Kuei Fu
PRINCIPAL INVESTIGATOR
Department of Chest Medicine of Taichung Veterans General
Frequently Asked Questions
Who can join the NCT05926713 clinical trial?
This trial is open to participants of all sexes, studying Sarcopenia. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05926713 currently recruiting?
Yes, NCT05926713 is actively recruiting participants. Contact the research team at yetquen@vghtc.gov.tw for enrollment information.
Where is the NCT05926713 trial being conducted?
This trial is being conducted at Taichung, Taiwan.
Who is sponsoring the NCT05926713 clinical trial?
NCT05926713 is sponsored by Orient Europharma Co., Ltd.. The principal investigator is Pin-Kuei Fu at Department of Chest Medicine of Taichung Veterans General. The trial plans to enroll 100 participants.